Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 125
- Registration Number
- NCT00429260
- Locations
- 🇺🇸
Administrative Office, Malvern, Pennsylvania, United States
Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)
- Conditions
- Sleep Initiation and Maintenance Disorders
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1025
- Registration Number
- NCT00425243
- Locations
- 🇺🇸
Sanofi-Aventis, Malvern, Pennsylvania, United States
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 165
- Registration Number
- NCT00425191
- Locations
- 🇮🇹
Sanofi-Aventis, Milan, Italy
ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 88
- Registration Number
- NCT00424853
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00424905
- Locations
- 🇮🇹
Sanofi-Aventis, Milan, Italy
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin glargine (LANTUS)
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2009-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1007
- Registration Number
- NCT00423215
- Locations
- 🇮🇱
Sanofi-Aventis Administrative Office, Natanya, Israel
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
- Conditions
- Tumors
- Interventions
- Drug: bsi-201 + carboplatin/paclitaxel
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT00422682
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2011-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT00421824
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
- Conditions
- Pancreatic Neoplasms
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 408
- Registration Number
- NCT00417209
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
- Conditions
- NeoplasmsProstatic Neoplasms
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 755
- Registration Number
- NCT00417079
- Locations
- 🇭🇺
Sanofi-Aventis Hungaria, Budapest, Hungary
🇫🇮sanofi-aventis Finland, Helsinki, Finland
🇮🇳sanofi-aventis India, Mumbai, India